Search
Displaying 571–580 of 929 results for “vision connection”
-
Ashlyn Experiences Joy in Day-To-Day Life After Sight Is Restored
Beacon StoriesAshlyn’s vision was restored following her treatment with the LUXTURNA gene therapy.
-
FDA Authorizes Stem Cell Clinical Trial for RP in Los Angeles
Research NewsPhase 1/2a human study will evaluate neural progenitors for preserving vision
-
Beacon Stories
13 year old Kailey Reichardt’s personal essay about her little sister Ashlyn, who was diagnosed with Leber congenital amarosis (LCA) at a young age. Kailey is a Beacon for other siblings impacted and going through similar situations.
-
The Retina is a Proving Ground for a Broad Range of Neurological Therapies
Research NewsRetinal research paves the way for new treatments for the entire neurological system.
-
Information for affected individuals and their families about the role of genetic counseling.
-
First Patient Receives ProQR’s Emerging USH2A Therapy in Clinical Trial
Research NewsProQR, a developer of RNA therapies in the Netherlands, announced that the first clinical-trial participant has received its emerging treatment, which targets retinitis pigmentosa and Usher syndrome caused by mutations in exon 13 of the USH2A gene.
-
The Foundation Fighting Blindness and Dr. H. James & Carole Free Collaborate to Combat AMD
Foundation NewsAge-related macular degeneration (AMD) is the leading cause of blindness for people over 50 years of age in developed countries.
-
FDA Authorizes Clinical Trial for CRISPR/Cas9 Therapy for LCA 10
Research NewsEditas Medicine, a company developing gene-editing treatments, has received authorization from the US Food and Drug Administration to launch a clinical trial for its emerging CRISPR/Cas9 therapy for people with a mutation in the gene CEP290, which causes Leber congenital amaurosis 10 (LCA10). LCA causes severe vision loss or blindness at birth.
-
ProQR Receives FDA Authorization to Launch Clinical Trial for USH2A Therapy
Research NewsProQR, a biotech in the Netherlands developing therapies for rare diseases, has received authorization from the US Food and Drug Administration to launch a Phase I/II clinical trial for QR-421a, its treatment targeting mutations in exon 13 of the USH2A gene.
